Email Alert | RSS    帮助

中国防痨杂志 ›› 2025, Vol. 47 ›› Issue (3): 262-265.doi: 10.19982/j.issn.1000-6621.20250006

• 专题笔谈 • 上一篇    下一篇

18F海藻糖-PET-CT技术或将为结核病临床研究带来革命性改变

张培泽1,2, 高谦2, 邓国防1,2()   

  1. 1深圳市第三人民医院肺病医学部/深圳市结核病临床医学研究中心,深圳 518112
    2国家感染性疾病临床医学研究中心,深圳 518112
  • 收稿日期:2025-01-06 出版日期:2025-03-10 发布日期:2025-02-27
  • 通信作者: 邓国防,Email:jxxk1035@yeah.net
  • 基金资助:
    广东省结核病临床研究中心(2020B1111170014);深圳市结核病临床研究中心(20210617141509001);深圳市第三人民医院课题(G2021023);深圳市第三人民医院课题(G2022155)

[18F]FDT-PET-CT technology that may bring revolutionary changes to tuberculosis clinical research

Zhang Peize1,2, Gao Qian2, Deng Guofang1,2()   

  1. 1Department of Pulmonary Medicine, The Third People’s Hospital of Shenzhen/Shenzhen Clinical Research Center for Tuberculosis,Shenzhen 518112, China
    2The National Clinical Research Center for Infectious Diseases, Shenzhen 518112, China
  • Received:2025-01-06 Online:2025-03-10 Published:2025-02-27
  • Contact: Deng Guofang, Email: jxxk1035@yeah.net
  • Supported by:
    Tuberculosis Clinical Research Center of Guangdong Province(2020B1111170014);Shenzhen Clinical Research Center for Tuberculosis(20210617141509001);Project of Shenzhen Third People’s Hospital(G2021023);Project of Shenzhen Third People’s Hospital(G2022155)

摘要:

目前,结核病临床疗效评价依赖于传统的细菌学及影像学手段,难以满足临床需要。近期,Khan 等报告了使用18F海藻糖(2-[18F]Fluoro-2-deoxy-trehalose, [18F]FDT)标记体内活性结核分枝杆菌并通过PET-CT成像的技术。该技术使用[18F]FDT实现了非人类的灵长类动物体内活性结核分枝杆菌的成像,并通过抗结核治疗前后[18F]FDT摄取率的变化反映结核病的治疗疗效;而且,[18F]FDT是主要经肾脏排泄的一种安全性良好的示踪剂。笔者认为,该技术的开发可能在结核病治疗终点判断、活动性结核病鉴别诊断、药物疗效判断及抗结核新药和疫苗研发等领域具有广阔的应用前景。本文中,笔者将该技术的成像原理、动物模型的研究结果作简要介绍,并探讨其在结核病临床研究中的应用场景,以供同行参考。

关键词: 结核, 海藻糖, 同位素标记, 正电子发射断层显像术, 综述文献(主题)

Abstract:

Current tuberculosis treatment monitoring relies on traditional bacteriological and imaging methods, which are insufficient to meet clinical needs. Recently, Khan et al. reported a novel approach to image live Mycobacterium tuberculosis (MTB) in vivo via PET-CT using [18F]Fluoro-2-deoxy-trehalose (2-[18F]FDT), a reporter of mycobacteria-selective enzyme activity. This technique images live MTB in non-human primates and monitor the effects of treatment through the change of [18F]FDT uptake. Moreover, [18F]FDT is a safe tracer that is primarily excreted via the kidneys. We believe that this technology holds great potential for applications in determining tuberculosis treatment endpoints, differentiating active tuberculosis, assessing drug efficacy, and accelerating the development of anti-tuberculosis drugs and vaccines. We provide a brief overview of the imaging principles and preliminary findings of this technology, as well as a discussion of its potential applications of tuberculosis clinical researches for peer references.

Key words: Tuberculosis, Trehalose, Isotope labeling, Positron-emission tomography, Review literature as topic

中图分类号: